m+Medelevator.RU
← Поиск публикаций
Indian journal of nephrology · 2025

Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors for Treatment of Anemia in Chronic Kidney Disease: Guidelines for South Asia.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

South Asia HIF-PHI for Anemia in CKD Guideline Development Group, Abraham Abi, Almeida Alan, Bhalla Anil Kumar, Chaudury Arpita Ray, Dutta Arup Ratan, Gupta Ashwani, Shah Bharat, Roy Biswajeet, Subbarao Budithi, Herath Chula, Amrutha Cynthia, Shah Dibya Singh, Pahari Dilip Kumar, Khullar Dinesh, Bajpai Divya, Simaladinne Guruvulu Venkata, Kothari Jatin, Tyagi Jyoti, Sharma Inika, Shah Kamal, Malik Manish, Sahay Manisha, Sharma Manjuri, Gumber Manoj, Sreelatha Melemadathil, Tiwaskar Mangesh, Kaur Manveen, Alam Muhammed Rafiqul, Gopalakrishnan Natarajan, Prasad Narayan, Kamath Nivedita, Meena Priti, Varma Prem Prakash, Das Pratik, Ramachandran Raja, Sharma Raj Kumar, George Reena, Jain Salil, Ingale Samiksha, Moola Sandeep, Bhattacharya Sandip Kumar, D'Cruz Sanjay, Gulati Sanjeev, Saxena Sanjiv, Sundar Sankaran, Acharya Shivnarayan, Bansal Shyam Bihari, Vishwanath Siddini, Gang Sishir, Raju Sree Bhushan, Parameswaran Sreejith, Bhaumik Soumyadeep, Madhu Sri Venkata, Alexander Suceena, Jeloka Tarun, Saha Tarun Kumar, Das Tonmoy, Anandh Urmila, Khanna Umesh, Bhatia Virat, Saxena Vishal, Kher Vijay, Raghavan Vasundhara, Jha Vivekanand, *Steering Committee†, Methodology Committee (non-voting)#, Guideline Development Panel$

Аннотация

This guideline addresses the use of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) in patients >18 years with chronic kidney disease (CKD) and anemia in South Asia (Bangladesh, Bhutan, Nepal, India, Pakistan, Sri Lanka). It also summarizes recommendations for anemia treatment for individual HIF-PHI molecules under two categories: dialysis-dependent and non-dialysis-dependent CKD patients. The recommendations do not apply to pediatric (≤12 years) and adolescent (12 to 18) patients or those with primary anemia or anemia secondary to other causes such as blood loss, cancer (any type), polycystic kidney disease and infectious diseases.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты